Analyzing Adlai Nortye (NASDAQ:ANL) and MoonLake Immunotherapeutics (NASDAQ:MLTX)

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Adlai Nortye (NASDAQ:ANL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Earnings & Valuation

This table compares MoonLake Immunotherapeutics and Adlai Nortye”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$118.94 million	($3.32)	-3.20
Adlai Nortye	$5.00 million	11.44	-$51.87 million	N/A	N/A

Adlai Nortye has higher revenue and earnings than MoonLake Immunotherapeutics.

Institutional and Insider Ownership

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 35.2% of Adlai Nortye shares are held by institutional investors. 12.1% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

MoonLake Immunotherapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Adlai Nortye has a beta of -0.88, suggesting that its stock price is 188% less volatile than the S&P 500.

Profitability

This table compares MoonLake Immunotherapeutics and Adlai Nortye’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-55.57%	-45.18%
Adlai Nortye	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and price targets for MoonLake Immunotherapeutics and Adlai Nortye, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3	7	5	0	2.13
Adlai Nortye	1	1	0	0	1.50

MoonLake Immunotherapeutics presently has a consensus price target of $30.58, suggesting a potential upside of 187.71%. Adlai Nortye has a consensus price target of $9.00, suggesting a potential upside of 480.65%. Given Adlai Nortye’s higher probable upside, analysts plainly believe Adlai Nortye is more favorable than MoonLake Immunotherapeutics.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.